Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad-HDGF siRNA
- Development stage
- Preclinical
- Lead developer
- I-Shou University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies
- Administration
- Intratumoral
01
Overview
Ad-HDGF siRNA is an adenoviral vector-based gene therapy designed to deliver small interfering RNA (siRNA) targeting hepatoma-derived growth factor (HDGF). HDGF is a heparin-binding protein that acts as a mitogenic and neurotrophic factor, often overexpressed in various cancers, including gliomas, where it promotes tumor progression, cell invasion, and survival. By utilizing an adenoviral delivery system, this agent achieves efficient knockdown of nuclear HDGF expression in target cells. In preclinical models of glioblastoma multiforme (GBM), treatment with Ad-HDGF siRNA has been shown to inhibit cell proliferation and invasion while inducing apoptosis through caspase-3 activation. It was primarily researched by investigators at I-Shou University and Kaohsiung Veterans General Hospital in Taiwan as a potential therapeutic strategy for malignant gliomas.
- Other names
- Adenoviral-expressed HDGF siRNAAdenovirus-mediated HDGF siRNA
02
Targets
HDGF (Hepatoma-derived growth factor)
Beyond the preview
Go deeper on Ad-HDGF siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad-HDGF siRNA.